Markets · 1 sources covering this

Texas Stock Exchange Heralds Debut With Sights on NYSE, Nasdaq

The Texas Stock Exchange has rolled out trading for all tickers as the upstart venue steps up its drive to win business from Nasdaq and the New York Stock Exchange.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
Texas Stock Exchange Heralds Debut With Sights on NYSE, Nasdaq
The Texas Stock Exchange has rolled out trading for all tickers as the upstart venue steps up its drive to win business from Nasdaq and the New York Stock Exchange.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/c9d2dbd60d58faca9e4eed91a20d045a6d9ca43d"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Texas Stock Exchange Heralds Debut With Sights on NYSE, Nasdaq"></iframe>

Texas Stock Exchange Heralds Debut With Sights on NYSE, Nasdaq

How 1 sources are covering this

Texas Stock Exchange Heralds Debut With Sights on NYSE, Nasdaq

More from Markets

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years

Situational Awareness Losses Raise AI Fears

Why 3 Fed dissenters say waiting to raise interest rates could make inflation harder to tame

Reader

Trust & legal

Across the network

How 1 sources are covering this

Texas Stock Exchange Heralds Debut With Sights on NYSE, Nasdaq

More from Markets

Novo Nordisk&#x2019;s stock slumps after failed trial &#x2014; adding to the company&#x2019;s woes

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years

Situational Awareness Losses Raise AI Fears

Why 3 Fed dissenters say waiting to raise interest rates could make inflation harder to tame

Reader

Trust & legal

Across the network

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes